Skip to Content
Merck
  • The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage.

The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage.

PeerJ (2017-10-25)
Justin Y D Lu, Ping Su, James E M Barber, Joanne E Nash, Anh D Le, Fang Liu, Albert H C Wong
ABSTRACT

Clinical evidence points to neuroprotective effects of smoking in Parkinson's disease (PD), but the molecular mechanisms remain unclear. We investigated the pharmacological pathways involved in these neuroprotective effects, which could provide novel ideas for developing targeted neuroprotective treatments for PD. We used the ETC complex I inhibitor methylpyridinium ion (MPP

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyllycaconitine citrate salt, from Delphinium brownii seeds, ≥96% (HPLC)
Sigma-Aldrich
Triton X-100, laboratory grade